Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
Objectives: The aim of this study was to examine the discontinuation and occurrence of fracture during denosumab treatment in Japanese women with primary osteoporosis or rheumatoid arthritis (RA) with osteoporosis. Methods: This retrospective study included 143 patients with primary osteoporosis and...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-06-01
|
Series: | Osteoporosis and Sarcopenia |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405525517300080 |
id |
doaj-98d595012e3143f9b0514e33169b945d |
---|---|
record_format |
Article |
spelling |
doaj-98d595012e3143f9b0514e33169b945d2020-11-24T23:25:22ZengElsevierOsteoporosis and Sarcopenia2405-52552017-06-013210811110.1016/j.afos.2017.03.003Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosisTakako Suzuki0Yukio Nakamura1Mikio Kamimura2Shota Ikegami3Shigeharu Uchiyama4Hiroyuki Kato5Department of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, JapanDepartment of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, JapanCenter of Osteoporosis and Spinal Disorders, Kamimura Orthopaedic Clinic, Matsumoto, JapanDepartment of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, JapanDepartment of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, JapanDepartment of Orthopaedic Surgery, Shinshu University School of Medicine, Matsumoto, JapanObjectives: The aim of this study was to examine the discontinuation and occurrence of fracture during denosumab treatment in Japanese women with primary osteoporosis or rheumatoid arthritis (RA) with osteoporosis. Methods: This retrospective study included 143 patients with primary osteoporosis and 96 patients with RA and osteoporosis who were treated with denosumab. Treatment discontinuation, fracture occurrence, lumbar spine (L1–4) bone mineral density (LS-BMD), and bilateral total hip BMD (TH-BMD) were examined before and at 1 and 2 years after treatment commencement. Results: In the primary osteoporosis group, 32 cases dropped out and no fractures occurred from 0 to 1 year. Eighteen cases were lost to follow-up and no fractures were noted from 1 to 2 years. In the RA with osteoporosis group, 7 cases dropped out and no fracture occurred from 0 to 1 year. Twenty-one cases were lost to follow-up and 2 nonvertebral fractures were noted from 1 to 2 years. In this group, 13 cases dropped out from 1 to 2 years and 16 cases dropped out during the 2-year study period due to economic reasons. LS-BMD and TH-BMD values increased continuously for 2 years of treatment in both primary osteoporosis and RA with osteoporosis groups. Conclusions: These results suggest that during denosumab therapy, the discontinuation rate is expected to remain low during 2 years of treatment in primary osteoporotic patients. In RA patients with osteoporosis, however, the discontinuation rate may increase due to economic reasons from 1 to 2 years of therapy.http://www.sciencedirect.com/science/article/pii/S2405525517300080DenosumabDiscontinuationFractureOsteoporosisRheumatoid arthritis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Takako Suzuki Yukio Nakamura Mikio Kamimura Shota Ikegami Shigeharu Uchiyama Hiroyuki Kato |
spellingShingle |
Takako Suzuki Yukio Nakamura Mikio Kamimura Shota Ikegami Shigeharu Uchiyama Hiroyuki Kato Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis Osteoporosis and Sarcopenia Denosumab Discontinuation Fracture Osteoporosis Rheumatoid arthritis |
author_facet |
Takako Suzuki Yukio Nakamura Mikio Kamimura Shota Ikegami Shigeharu Uchiyama Hiroyuki Kato |
author_sort |
Takako Suzuki |
title |
Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis |
title_short |
Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis |
title_full |
Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis |
title_fullStr |
Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis |
title_full_unstemmed |
Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis |
title_sort |
compliance and discontinuation of denosumab treatment in postmenopausal japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis |
publisher |
Elsevier |
series |
Osteoporosis and Sarcopenia |
issn |
2405-5255 |
publishDate |
2017-06-01 |
description |
Objectives: The aim of this study was to examine the discontinuation and occurrence of fracture during denosumab treatment in Japanese women with primary osteoporosis or rheumatoid arthritis (RA) with osteoporosis.
Methods: This retrospective study included 143 patients with primary osteoporosis and 96 patients with RA and osteoporosis who were treated with denosumab. Treatment discontinuation, fracture occurrence, lumbar spine (L1–4) bone mineral density (LS-BMD), and bilateral total hip BMD (TH-BMD) were examined before and at 1 and 2 years after treatment commencement.
Results: In the primary osteoporosis group, 32 cases dropped out and no fractures occurred from 0 to 1 year. Eighteen cases were lost to follow-up and no fractures were noted from 1 to 2 years. In the RA with osteoporosis group, 7 cases dropped out and no fracture occurred from 0 to 1 year. Twenty-one cases were lost to follow-up and 2 nonvertebral fractures were noted from 1 to 2 years. In this group, 13 cases dropped out from 1 to 2 years and 16 cases dropped out during the 2-year study period due to economic reasons. LS-BMD and TH-BMD values increased continuously for 2 years of treatment in both primary osteoporosis and RA with osteoporosis groups.
Conclusions: These results suggest that during denosumab therapy, the discontinuation rate is expected to remain low during 2 years of treatment in primary osteoporotic patients. In RA patients with osteoporosis, however, the discontinuation rate may increase due to economic reasons from 1 to 2 years of therapy. |
topic |
Denosumab Discontinuation Fracture Osteoporosis Rheumatoid arthritis |
url |
http://www.sciencedirect.com/science/article/pii/S2405525517300080 |
work_keys_str_mv |
AT takakosuzuki complianceanddiscontinuationofdenosumabtreatmentinpostmenopausaljapanesewomenwithprimaryosteoporosisorrheumatoidarthritisandosteoporosis AT yukionakamura complianceanddiscontinuationofdenosumabtreatmentinpostmenopausaljapanesewomenwithprimaryosteoporosisorrheumatoidarthritisandosteoporosis AT mikiokamimura complianceanddiscontinuationofdenosumabtreatmentinpostmenopausaljapanesewomenwithprimaryosteoporosisorrheumatoidarthritisandosteoporosis AT shotaikegami complianceanddiscontinuationofdenosumabtreatmentinpostmenopausaljapanesewomenwithprimaryosteoporosisorrheumatoidarthritisandosteoporosis AT shigeharuuchiyama complianceanddiscontinuationofdenosumabtreatmentinpostmenopausaljapanesewomenwithprimaryosteoporosisorrheumatoidarthritisandosteoporosis AT hiroyukikato complianceanddiscontinuationofdenosumabtreatmentinpostmenopausaljapanesewomenwithprimaryosteoporosisorrheumatoidarthritisandosteoporosis |
_version_ |
1725557983675416576 |